Activity of oritavancin against gram-positive clinical isolates responsible for documented skin and soft-tissue infections in european and us hospitals (2010-13)

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 498-504

  Mendes, Rodrigo E ^a   Farrell, David J ^a   Sader, Helio S ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Bactericidal; Lipoglycopeptides; SSTIs

Indexed keywords

AMPICILLIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; ORITAVANCIN; PENICILLIN DERIVATIVE; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; GRAM POSITIVE BACTERIUM; HOSPITAL; HUMAN; IN VITRO STUDY; ISRAEL; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS PYOGENES; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANTIBIOTIC RESISTANCE; CLASSIFICATION; CLINICAL TRIAL; CROSS INFECTION; DRUG EFFECTS; GRAM-POSITIVE BACTERIAL INFECTIONS; HEALTH SURVEY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; EUROPE; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PUBLIC HEALTH SURVEILLANCE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; UNITED STATES;

EID: 84922439692     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku421     Document Type: Article

References (21)

1. Moran GJ, Abrahamian FM, Lovecchio F et al. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. J Emerg Med 2013; 44: e397-412.
2. Li M, Diep BA, Villaruz AE et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci USA 2009; 106: 5883-8.
3. Talan DA, Krishnadasan A, Gorwitz RJ et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011; 53: 144-9.
4. Sherwood J, Park M, Robben P et al. USA300 methicillin-resistant Staphylococcus aureus emerging as a cause of bloodstream infections at military medical centers. Infect Control Hosp Epidemiol 2013; 34: 393-9.
5. Vergison A, Nobre Machado A, Deplano A et al. Heterogeneity of disease and clones of community-onsetmethicillin-resistant Staphylococcus aureus in children attending a paediatric hospital in Belgium. Clin Microbiol Infect 2012; 18: 769-77.
6. Antri K, Rouzic N, Dauwalder O et al. High prevalence of methicillinresistant Staphylococcus aureus clone ST80-IV in hospital and community settings in Algiers. Clin Microbiol Infect 2011; 17: 526-32.
7. Hanssen AM, Fossum A, Mikalsen J et al. Dissemination of community-acquired methicillin-resistant Staphylococcus aureus clones in northern Norway: sequence types 8 and 80 predominate. J Clin Microbiol 2005; 43: 2118-24.
8. Larsen AR, Bocher S, Stegger M et al. Epidemiology of European community-associated methicillin-resistant Staphylococcus aureus clonal complex 80 type IV strains isolated in Denmark from 1993 to 2004. J Clin Microbiol 2008; 46: 62-8.
9. Zervos MJ, Freeman K, Vo L et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012; 50: 238-45.
10. Garau J, Ostermann H, Medina J et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013; 19: E377-85.
11. Marra F, Patrick DM, Chong M et al. Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use. Antimicrob Agents Chemother 2012; 56: 6243-9.
12. Diep BA, Chambers HF, Graber CJ et al. Emergence of multidrugresistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008; 148: 249-57.
13. McDougal LK, Fosheim GE, Nicholson A et al. Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob Agents Chemother 2010; 54: 3804-11.
14. Witte W. Community-acquired methicillin-resistant Staphylococcus aureus: What do we need to know?. Clin Microbiol Infect 2009; 15 Suppl 7: 17-25.
15. The Medicines Company. OrbactivTM. http://www.orbactiv.com.
16. Corey GR, Kabler H, Mehra P et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. New Engl J Med 2014; 370: 2180-90.
17. Corey R, Perez A, Moeck G et al. A single-dose of oritavancin is comparable to 7-10 days of vancomycin in the treatment of acute bacterial skin and skin structure infections (ABSSSI): the SOLO II study. In: Abstracts of the Fifty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013. Abstract L-206c. Washington, DC: American Society for Microbiology.
18. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
19. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
20. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, version 4.0, January 2014. http://www.eucast.org/clinical_breakpoints/.
21. Mendes RE, Sader HS, Flamm RK et al. Oritavancin activity against Staphylococcus aureus causing invasive infections in USA and European hospitals. A five-year international surveillance program. Antimicrob Agents Chemother 2014; 58: 2921-4.